Hematologic malignancy
Conditions
Interventions
Dual therapy combined with aprepitant and 5HT3 receptor antagonist
Sponsors
Department of Hematology and Oncology, Kurume University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with hematologic malignancy receiving who first underwent highly emetogenic chemotherapy (the same patient receiving different regimen is allowed) 2) Written informed consent for participation in the study
Exclusion criteria
Exclusion criteria: 1) Patient has a serious hepatic insufficiency or renal failure 2) Patient has nausea or vomiting within 24 hours prior to chemotherapy 3) Patient has been treated with antiemetic agents within 24 hours prior to chemotherapy 4) Patient has any illness (e.g. central nervous system tumors, gastrointestinal obstruction, active peptic ulcer, brain metastasis) caused nausea or vomiting except for chemotherapy-induced nausea and vomiting 5) Patient is pregnant or lactating woman, and woman who plans to become pregnant 6) Patient is currently treated with pimozide 7) Patient is judged inappropriate by the investigator as subject for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Proportion of patients with no emesis 2) Proportion of patients with no nausea and no more than mild nausea | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Proportion of patients with complete response (no emesis and no use of rescue medication) 2) Proportion of patients with complete protection (no emesis, no use of rescue medication, and no more than mild nausea) 3) Distribution of incidences of nausea and vomiting 4) Time to first emetic episode and time to first use of rescue medication 5) Food ingestion 6) Change in body weight | — |
Countries
Japan
Outcome results
None listed